ResearchWorks Archive

Sieve Analysis: Statistical Methods for Assessing Genotype-Specific Vaccine Protection in HIV-1 Efficacy Trials with Multivariate and Missing Genotypes

Show simple item record

dc.contributor.advisor Gilbert, Peter B en_US Juraska, Michal en_US 2012-09-13T17:33:18Z 2012-09-13T17:33:18Z 2012-09-13 2012 en_US
dc.identifier.other Juraska_washington_0250E_10251.pdf en_US
dc.description Thesis (Ph.D.)--University of Washington, 2012 en_US
dc.description.abstract The extensive diversity of the human immunodeficiency virus type 1 (HIV-1) poses a major challenge for the design of a successful preventive HIV-1 vaccine. Thus an important component of HIV-1 vaccine development is the assessment of the impact of HIV-1 diversity on vaccine protection against HIV-1 acquisition. Statistical methods to evaluate whether and how vaccine efficacy depends on genetic features of exposing viruses in data collected in randomized double-blinded placebo-controlled Phase IIb/III preventive HIV-1 vaccine efficacy trials are developed. To characterize exposing HIV-1 strains, their genetic distances to the multiple HIV-1 sequences included in the vaccine construct are measured, where the set of genetic distances is considered as the continuous multivariate `mark' observable in infected subjects only. A mark-specific vaccine efficacy model is described in the framework of competing risks failure time analysis that allows improved efficiency of estimation, relative to current alternative approaches, by using the semiparametric method of maximum profile likelihood estimation in the vaccine-to-placebo mark density ratio model. In addition, the model allows to employ a more efficient estimation method for the overall hazard ratio in the Cox model. Mark data proximal to the time of HIV-1 acquisition, that are of greatest biological relevance, are commonly subject to missingness due to the intra-host HIV-1 evolution. Two inferential approaches accommodating missing marks are proposed: (i) weighting of the complete cases by the inverse probabilities of observing the mark of interest (Horvitz and Thompson, 1952), and (ii) augmentation of the inverse probability weighted estimating functions for improved efficiency and model robustness by leveraging auxiliary information predictive of the mark (using the general theory of Robins, Rotnitzky, and Zhao (1994)). The missing-mark methods provide a general framework for parameter estimation in density ratio/biased sampling models in the presence of missing data. The proposed methodology can serve either to make inference about whether and how vaccine efficacy varies with prespecified genetic distance measures, or as an exploratory tool to identify distance definitions with the greatest decline in vaccine efficacy, characterizing potential correlates of immune protection and indicating pathways for improved HIV-1 vaccine design. The developed methods are applied to HIV-1 sequence data collected in the RV144 Phase III preventive HIV-1 vaccine efficacy trial. en_US
dc.format.mimetype application/pdf en_US
dc.language.iso en_US en_US
dc.rights Copyright is held by the individual authors. en_US
dc.subject competing risks; density ratio model; inverse probability weighting; mark-specific vaccine efficacy; mark variable; missing marks en_US
dc.subject.other Biostatistics en_US
dc.subject.other Biostatistics en_US
dc.title Sieve Analysis: Statistical Methods for Assessing Genotype-Specific Vaccine Protection in HIV-1 Efficacy Trials with Multivariate and Missing Genotypes en_US
dc.type Thesis en_US
dc.embargo.terms No embargo en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ResearchWorks

Advanced Search


My Account